SARS (Severe Acute Respiratory Syndrome)

Respiratory
1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Disco Pharmaceuticals
Disco PharmaceuticalsGermany - Cologne
1 program
1
To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccinePhase 3Vaccine
CeGaT
CeGaTGermany - Tubingen
1 program
Ion Mobility SpectrometryN/A1 trial
Active Trials
NCT04649931CompletedEst. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CeGaTIon Mobility Spectrometry

Clinical Trials (1)

NCT04649931CeGaTIon Mobility Spectrometry

Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease)

Start: Dec 2020Est. completion: Apr 2021
N/ACompleted

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space